CAS Number: 956104-40-8

Stage: Pipeline

Apalutamide is a next-generation androgen receptor inhibitor developed for non-metastatic CRPC and metastatic castration-sensitive prostate cancer (mCSPC). It prevents androgen receptor translocation and DNA binding, offering improved outcomes and delayed disease progression. Apalutamide is part of a growing class of targeted prostate cancer therapies. Explore Royal Pharma as your potential partner for Apalutamide API.